Several silver foil pill packs with white pills
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19
Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.
ABOVE: © ISTOCK.COM, KENISHIROTIE
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19
FDA Authorizes Pfizer’s Paxlovid, First Oral Therapy for COVID-19

Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.

Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.

ABOVE: © ISTOCK.COM, KENISHIROTIE

antiviral therapy

Updated
Merck research facility in San Francisco
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Chloe Tenn | Oct 1, 2021
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
the molecular structure of interferon-alpha
Lots of Rapid Evolution in Interferon-Stimulated Genes: Study
Christie Wilcox | Jul 1, 2021
A comparison of interferon-related genes across 20 primate genomes reveals differences in the speed at which they evolve and new targets for antiviral discovery efforts.
Fast-Tracking COVID-19 Research
The Scientist Creative Services Team in collaboration with Sartorius Corporation | Mar 17, 2021
Identifying molecular targets for SARS-CoV-2 therapeutics.
2020 in Scientists’ Own Words
Abby Olena | Dec 23, 2020
The world was rocked by the COVID-19 pandemic this year, but researchers rose to all manner of challenges.
Researchers Who Discovered Hepatitis C Earn Nobel Prize
Max Kozlov | Oct 5, 2020
Harvey Alter, Michael Houghton, and Charles Rice share the Physiology or Medicine award for their contributions to identifying the virus and demonstrating that it was responsible for hepatitis among blood transfusion recipients.
The Scientist Speaks Podcast - Episode 9
The Scientist Creative Services Team | Sep 29, 2020
Repurposing Living Systems to Fight a Pandemic
Gilead Urged to Explore Remdesivir Relative as COVID-19 Drug
Catherine Offord | Aug 11, 2020
Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.
AI Is Screening Billions of Molecules for Coronavirus Treatments
Abby Olena | May 7, 2020
Machine learning has pegged existing drugs to repurpose for COVID-19 clinical trials.
Combating COVID-19 with Cell-Free Expression
The Scientist Creative Services Team | Aug 19, 2020
Scientists rely on synthetic biology and cell-free expression systems for developing novel approaches to combat the pandemic.
Remdesivir Shows Promise in Largest of Several Clinical Trials
Catherine Offord | Apr 30, 2020
Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.
chloroquine hydroxychloroquine covid-19 coronavirus sars-cov-2 malaria antimalarial antiviral
Chloroquine for COVID-19: Cutting Through the Hype
Chris Baraniuk | Mar 20, 2020
President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.
Remdesivir Works Against Coronaviruses in the Lab
Abby Olena | Mar 20, 2020
The antiviral disables RNA replication machinery in MERS and SARS viruses. Can it beat back SARS-CoV-2?
The Latest Drug Trials for Coronavirus
Ashley Yeager | Feb 18, 2020
Under careful watch of the World Health Organization, doctors will test a range of COVID-19 therapies, including HIV and flu antivirals, blood plasma infusions, and traditional Chinese medicines.
Flu and HIV Drugs Show Efficacy Against Coronavirus
Catherine Offord | Feb 3, 2020
Combining the medications improved conditions in patients with severe 2019-nCoV infections, say doctors in Thailand.
Novel DNA-Sensing Pathway Found in Human Cells, Absent in Mice
Catherine Offord | Jan 24, 2020
This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.
flu influenza xofluza virus drug-resistant baloxavir
Drug-Resistant Flu Can Emerge After Patients Take Antiviral
Kerry Grens | Nov 26, 2019
Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug.
Two Experimental Drugs Effective at Treating Ebola
Catherine Offord | Aug 13, 2019
REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.
Many Non-Antibiotic Drugs Affect Gut Bacteria
Catherine Offord | Mar 19, 2018
A new study finds that more than 200 human-targeted, non-antibiotic drugs inhibit the growth of bacterial species that make up part of the human microbiome.
Flu Drug Approved in Japan Claims to Stop Virus in 24 Hours
Kerry Grens | Feb 25, 2018
One dose of the medication, called Xofluza, cripples influenza by interfering with an enzyme critical for viral replication.